Kisho

Glaukos Corporation — Rare Disease Pipeline | Kisho | Kisho

Glaukos Corporation

Other

Orphan Designations

FDA Approvals

Rare Diseases

News Articles

Disease	Drug(s)	Designation	Approved
Angelman syndrome	Photrexa Viscous	Orphan Designation	-
Bruck syndrome	mitomycin	Orphan Designation	-
Ramos-Arroyo syndrome	Antisense oligonucleotide directed against connexin43	Orphan Designation	-
abetalipoproteinemia	Photrexa Viscous	Orphan Designation	-
acrofacial dysostosis Cincinnati type	mitomycin	Orphan Designation	-
anterior segment dysgenesis 8	Antisense oligonucleotide directed against connexin43	Orphan Designation	-
central corneal ulcer	riboflavin 5'-phosphate sodium	Orphan Designation	-
corneal ectasia	Photrexa Viscous	Orphan Designation	-
corneal ulcer	riboflavin 5'-phosphate sodium	Orphan Designation	-
dermochondrocorneal dystrophy	mitomycin	Orphan Designation	-
epithelial and subepithelial corneal dystrophy	mitomycin	Orphan Designation	-
has an isolated presentation	Mitosol	Orphan Designation	-
keratoconus	copper sulfatePhotrexa Viscous	Orphan Designation	-
laryngo-onycho-cutaneous syndrome	mitomycin	Orphan Designation	-
mycotic corneal ulcer	riboflavin 5'-phosphate sodium	Orphan Designation	-
persistent hyperplastic primary vitreous, autosomal recessive	Antisense oligonucleotide directed against connexin43	Orphan Designation	-
progressive familial intrahepatic cholestasis	Photrexa Viscous	Orphan Designation	-
progressive supranuclear palsy	Photrexa Viscous	Orphan Designation	-
refractory celiac disease	Mitosol	Orphan Designation	-
refractory cytopenia of childhood	Mitosol	Orphan Designation	-
refractory hairy cell leukemia	Mitosol	Orphan Designation	-
refractory plasma cell neoplasm	Mitosol	Orphan Designation	-
subepithelial mucinous corneal dystrophy	mitomycin	Orphan Designation	-
testis refractory cancer	Mitosol	Orphan Designation	-

← Back to Companies